TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Rare Genetic Diseases Diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Adverse outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum pain on day of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum pain on postoperative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum pain on postoperative day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum pain on postoperative day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean power output during cycling performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: work of breathing (WOB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: expiratory flow limitation (EFL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Methylphenidate retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative acute lung injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants with Adverse Events (AEs) or Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: chance to avoid new caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: baseline-corrected Cmax of DHA total lipid & EPA total lipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baseline-corrected AUCt of DHA total lipid & EPA total lipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Success of Primary Vitrectomy Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: hematologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: FGF23 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pain measured by Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gut microbiota profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cytokines plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiac-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in symptoms of fibromyalgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and feasibility of curcumin
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Tumor Response at 9 Months After Last Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Patients With Grade 4 or Higher Renal Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Grade 4 or Higher Irreversible Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Weight From Baseline to 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Weight From Baseline to 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: performance in denomination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penile dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Peyronie's Disease
Endpoint domain: Adverse events/effects
Primary endpoint: AUCins.0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cins.max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUCGIR.0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Adjusted Mean HbA1c (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with HBV DNA levels < 300 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: major thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Insulin Resistance index (HOMA) at 60 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Lipids at 60 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Bioimpedance parameters at 60 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time nurses spend away from patients bedside
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Skin tissue image
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: User ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge Acquisition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Skills Acquisition
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean change in SNOT-22 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean change in NOSE score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Saliva Mutans streptococci and Lactobacilli levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confusion Assessment Method (CAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dose-Normalized Area Under the Concentration Versus Time Curve (AUC(0-∞)) in Cycle 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized Area Under the Concentration Versus Time Curve (AUC(0-∞)) in Cycle 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized Maximum Observed Drug Concentration (Cmax) in Cycle 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized Maximum Observed Drug Concentration (Cmax) in Cycle 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic biomarkers for anal SCC disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of immune analysis and NGS for treatment decisions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Renal Allograft Survival
Endpoint domain: Mortality/survival
Primary endpoint: Fitness status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory phenotype of circulating immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline IPQR score at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parent/Guardian Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hip Surveillance Program Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Economic Efficiency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC0-t - Area under the plasma concentration-time curve (AUC) from time zero to the last quantifiable concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf - AUC from time zero extrapolated to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of live births attended by a skilled health provider
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of TessArray microarray for respiratory infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in distance between ligaclips on lateral elbow radiographs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Masood Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Improvement From Baseline in Cytomorphologic Abnormality at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tyndall reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower extremity extensor power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PCL-5 Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provisional PTSD Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Hypertensive Phase After Ahmed Valve Implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure Control After Ahmed Valve Implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure of Eyes With Hypertensive Phase Versus Without Hypertensive Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with serum ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Urine Samples Containing TFV in Concentrations Greater Than or Equal to 1000ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of tracheal secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Opiate consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overall length of hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Antiviral activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of serum macrophage migration inhibitory factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: stage of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in children's emotional knowledge
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum Prostatic Specific Antigen (PSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Dosing Instances Taken Within 120 Hours of Unprotected Sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of Dosing Instances With No More Than One Tablet Taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Female Selectors Who Are Not Pregnant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of second PC passaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in HAMD-17
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in QEEG measurements (theta cordance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-related change in FDG metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with MRSA infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of acute rejection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality rate of cancer
Endpoint domain: Mortality/survival
Primary endpoint: Supine Slow Vital Capacity (SVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of benign surgeries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Major adverse events during index case
Endpoint domain: Adverse events/effects
Primary endpoint: Long term Brief Pain Inventory Scale Variation
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Diagnosis of psychological and psychiatric difficulties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean diurnal IOP (mm Hg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of Participants With Undetectable HCV-RNA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Aneurysm rupture
Endpoint domain: Mortality/survival
Primary endpoint: Forced Vital Capacity (FVC in L) at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Feasibility of geriatric fragility screening tool (D-FOG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute pain post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of low-dose CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of low-dose CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Antibody Titers >=1:4 and >=1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With >=4-Fold Rise in Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving hSBA Vaccine Seroresponse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Alterations of SSP-tendon in MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Patients With Reported Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of LHW090/LHV527 (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Patients Who Developed a Renal Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain Intensity Differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: event free survival at 2 years from CR achievement
Endpoint domain: Mortality/survival
Primary endpoint: event free survival at 2 years from diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients who survive relapse-free
Endpoint domain: Mortality/survival
Primary endpoint: % Excess Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Antioxidant effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of change in the Abnormal Involuntary Movement Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Successful inflation and maintenance of the fully inflated intragastric balloon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean voice onset time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Achieved Study Compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Lund-Kennedy Endoscopic Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Th17 cell counts in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in CD4 positive regulatory T cell counts in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in Th1 cell counts in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in Th2 cell counts in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Sleep Time Supine
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants Reporting at Least One Solicited Local or Systemic Reaction Post-Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Arterial function and structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of thyroid diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: DM1 alterations in human cardiomyocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma luteinizing hormone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: plasma testosterone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Efficiency of fibroblast epigenetic conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving cancer screening tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CIN 2/3 resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subject With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of externalizing disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of child's aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular profiling of plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CARE score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change of severity of breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Levels of streptococcus Mutans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Symptom Scoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival at hospital admission
Endpoint domain: Mortality/survival
Primary endpoint: Android fat distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence of Atrial fibrillation (AF free survival)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of low-intensity laser on oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breathing strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of women with pain in operated breast or vicinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in laboratory evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NIHSS score at Day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage Change of Preoperative Incentive Spirometry Volume Achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of COPD related re-hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rate of COPD related hospitalizations or death
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC) of Caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Facial Depigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Effectivity of irreversible electroporation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Exercise cardiopulmonary assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Conversion to psychosis
Endpoint domain: Mortality/survival
Primary endpoint: Poor function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Program feasibility based on participant attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Program feasibility based on practice logs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: glycemic levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve in plasma of IBD98-M
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Variation in asthmatic lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes